ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 89

Abatacept as Adjunct Therapy for the Calcinosis of Juvenile Dermatomyositis: A Single-Center Experience

Marietta DeGuzman1, Saimun Singla1, Melissa Mizesko2 and Anna Carmela Sagcal-Gironella3, 1Pediatric Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, 2Division of Rheumatology, Driscoll Children's Hospital, Corpus Christi, TX, 3Pediatric Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX

Meeting: 2017 Pediatric Rheumatology Symposium

Keywords: Abatacept, Calcinosis and juvenile dermatomyositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Thursday, May 18, 2017

Title: Clinical and Therapeutic Poster Session

Session Type: Abstract Submissions

Session Time: 5:30PM-7:00PM

Background/Purpose:

Juvenile dermatomyositis (JDMS) is an autoimmune inflammatory myopathy which primarily manifests with skin, muscle, and blood vessel involvement. Dystrophic calcification or calcinosis has been associated with aggressive disease and/or chronicity. It is usually difficult to control and may be associated with poor wound healing, risk for secondary skin/subcutaneous infection, and adverse quality of life due to pain, joint contractures, and altered mobility. Currently, there is no standard of care for JDMS associated calcinosis. There are limited case reports and clinical trials in JDMS on the use of abatacept, a fully human soluble fusion protein that prevents the costimulatory signaling required in T-cell activation. We describe our center’s experience in the use of abatacept in the treatment of JDMS associated calcinosis.

Methods:

A retrospective chart review of JDMS patients with calcinosis treated with abatacept at our center was performed after IRB approval. Collected data include patient demographics, clinical presentation and course, and therapy. Onset, clinical characteristics, and course of calcinosis following therapy with abatacept were described.

Results:

Four patients were included (females: 3, Hispanic ethnicity: 2). Median age at diagnosis was 4 years. Three patients had disease duration of 1 to 5 months prior to diagnosis, while one patient was diagnosed 48 months following disease onset. All patients had severe disease on presentation, and all received both IV and PO glucocorticoids, IVIG, methotrexate, and hydroxychloroquine. Two patients received rituximab. Median onset of calcinosis from disease onset was 18.5 months. All patients had a combination of superficial, interfascial, interarticular, and tumorous calcinosis. The median time for abatacept use following clinical diagnosis of calcinosis was 13.5 months (range: 5-25). Median duration of follow-up while on abatacept therapy was 13.5 months (range: 10-32). Clinical and imaging improvement of calcinosis were noted within 6-12 months of abatacept initiation. All patients had resolution of pain, tenderness, and inflammatory changes at the sites of calcinosis. Joint contractures related to calcinosis in two patients resolved within 3-5 months of abatacept use. Ulcer formation in one patient resolved. Secondary skin/subcutaneous infection was not observed in all patients despite use of combination immunosuppressive/immunomodulatory therapies. All patients remained free of disease flare throughout therapy.

Conclusion:

We described the clinical course and response to abatacept as adjunct therapy for calcinosis in four patients with juvenile dermatomyositis in this single-center retrospective review. Our patient outcomes suggest that abatacept may be an efficacious and safe treatment option in JDMS associated calcinosis. Further study in larger patient cohorts is warranted.


Disclosure: M. DeGuzman, None; S. Singla, None; M. Mizesko, None; A. C. Sagcal-Gironella, None.

To cite this abstract in AMA style:

DeGuzman M, Singla S, Mizesko M, Sagcal-Gironella AC. Abatacept as Adjunct Therapy for the Calcinosis of Juvenile Dermatomyositis: A Single-Center Experience [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 4). https://acrabstracts.org/abstract/abatacept-as-adjunct-therapy-for-the-calcinosis-of-juvenile-dermatomyositis-a-single-center-experience/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/abatacept-as-adjunct-therapy-for-the-calcinosis-of-juvenile-dermatomyositis-a-single-center-experience/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology